OTC Markets OTCPK - Delayed Quote USD

Aequus Pharmaceuticals Inc. (AQSZF)

Compare
0.0094 0.0000 (0.00%)
At close: October 31 at 4:00 PM EDT
Loading Chart for AQSZF
DELL
  • Previous Close 0.0000
  • Open 0.0084
  • Bid 0.0109 x --
  • Ask 0.0100 x --
  • Day's Range 0.0084 - 0.0084
  • 52 Week Range 0.0079 - 0.0343
  • Volume 4,000
  • Avg. Volume 702
  • Market Cap (intraday) 1.241M
  • Beta (5Y Monthly) -0.02
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0100
  • Earnings Date Nov 27, 2024 - Dec 2, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on commercializing value-added products in specialty therapeutic areas in Canada. The company markets and distributes ZIMED PF, a preservative-free bimatoprost prescription drug for the treatment of glaucoma. It also develops REV-0100 for the treatment of stargardt disease that is in pre-clinical trial. The company has a strategic collaboration with reVision for the development of a therapy for stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

www.aequuspharma.ca

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AQSZF

View More

Performance Overview: AQSZF

Trailing total returns as of 10/31/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AQSZF
56.22%
S&P/TSX Composite index
15.26%

1-Year Return

AQSZF
58.03%
S&P/TSX Composite index
28.11%

3-Year Return

AQSZF
89.87%
S&P/TSX Composite index
14.83%

5-Year Return

AQSZF
90.30%
S&P/TSX Composite index
46.39%

Compare To: AQSZF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AQSZF

View More

Valuation Measures

Annual
As of 10/31/2024
  • Market Cap

    953.58k

  • Enterprise Value

    4.86M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    8.03

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    31.40

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -178.79%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    278.2k

  • Net Income Avi to Common (ttm)

    -2.86M

  • Diluted EPS (ttm)

    -0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    44.08k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -1.79M

Research Analysis: AQSZF

View More

Company Insights: AQSZF

Research Reports: AQSZF

View More

People Also Watch